DaVita DVA
United StatesHealthcare · Medical Care FacilitiesUSD
219.86 USD (+24.4%)
7 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
DaVita Inc. is a leading provider of kidney dialysis services in the United States, operating dialysis centers and offering related services to patients with chronic kidney disease, generating revenue primarily through reimbursements from Medicare, Medicaid, and private insurers.
Key points
from its scores- ✓Good share-price trend9.2
- ✓Attractive valuation8.0
- ✓Strong growth7.0
- ✕Little or no dividend1.5
- ✕Fragile balance sheet4.5
AI analysis
bottom line, main risk, context and newsValuation is reasonable and earnings growth is strong, but monitor debt evolution and Medicare policies.
DaVita presents an attractive valuation (P/E 14.93, FCF yield 9.19%) and strong momentum (46.42% over 12 months), supported by an exceptional ROE of 88.48%, although its high leverage (Net Debt/EBITDA 4.5) and dependence on regulatory reimbursements add risk.
The main risk is regulatory exposure: changes in Medicare reimbursements or government investigations into billing practices could significantly impact revenues, along with high financial leverage that amplifies the impact of any regulatory pressure.
Context and risks
DaVita operates in the dialysis sector in the US, where Medicare reimbursement regulation and investigations into billing practices are recurring risks. The company has faced litigation and settlements with the government in the past, and any change in Medicare rates or health insurance policies can materially impact its revenues. Additionally, its high leverage (Net Debt/EBITDA of 4.5) makes it vulnerable to a rising interest rate environment, although the Fed could cut rates in September, which would alleviate pressure.
Is DaVita stock cheap or expensive?
at the analysis dateOn P/E and EV / EBITDA, it trades 40% below the Healthcare median on average.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| P/E | 14.9 | 26.7 | −44% |
| EV / EBITDA | 9.1 | 14.5 | −37% |
| Price / sales | 0.8 | 3.4 | −76% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 8.0 out of 10 (median for Healthcare: 4.7).
Average analyst target: 219.86 USD, +24.4% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 4.5 (sector 6.5), Growth 7.0 (sector 6.6).
Classic formulas with standard assumptions (10.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- P/E
- 14.9
- Forward P/E
- 10.3
- EV / EBITDA
- 9.1
- Price / book
- −14.8
- Price / sales
- 0.8
- PEG
- 0.44
- Market cap
- 11.3B USD
- Enterprise value
- 25.8B USD
Profitability
- ROE
- 88.5%
- ROA
- 7.5%
- Gross margin
- 32.4%
- Operating margin
- 16.1%
- Net margin
- 6.0%
- Free cash flow
- 1.0B USD
- FCF yield
- 9.2%
- Cash conversion
- 37%
Solvency
- Total debt
- 13.4B USD
- Net debt
- 12.7B USD
- Cash
- 688.9M USD
- EBITDA
- 2.8B USD
- Net debt / EBITDA
- 4.50
- Debt / equity
- 1,241.99
- Current ratio
- 1.47
- Quick ratio
- 1.33
Growth
- Revenue growth
- +5.2%
- Earnings growth
- +55.8%
- EPS (TTM)
- 11.84 USD
- EPS (forward)
- 17.14 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 0.80
- Analyst consensus
- Buy (7)
- Target price
- 219.86 USD
- 52-week range
- 101.00 – 247.49
Recent news
All DVA news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about DaVita
Is DaVita stock cheap or expensive?
On P/E and EV / EBITDA, it trades 40% below the Healthcare median on average. Valuation score: 8.0 out of 10 (median for Healthcare: 4.7). Average analyst target: 219.86 USD, +24.4% versus the price. This is not investment advice.
What score does DaVita get on MeridIAn Screener?
It scores 6.4 out of 10, rank 622 of 2,130 (better than 68% of the companies analysed). Its strongest category is Momentum (9.2) and its weakest, Dividend (1.5). Analysis of 08/10/2026.
What is DaVita's P/E ratio?
Its P/E is 14.9: the share price equals 14.9 times earnings per share over the last 12 months. The Healthcare median is 26.7. Based on the earnings analysts expect, the forward P/E is 10.3.
How much is DaVita worth on the stock market?
Its market capitalisation is 11.3B USD and its enterprise value, debt included, is 25.8B USD.
How much debt does DaVita have?
Its net debt (debt minus cash) is 12.7B USD. That is 4.50 times its EBITDA; the Healthcare median is 1.53.
Does DaVita pay a dividend?
It pays no dividend, or almost none.
How has DaVita stock performed over the last year?
It has risen 42.6% over the last year, excluding dividends. Over the last 52 weeks it has traded between 101.00 and 247.49 USD. Past performance does not guarantee future results.
What do analysts think of DaVita?
7 analysts cover it; their average recommendation is “Buy” and their average target is 219.86 USD (+24.4% versus the price). It is an estimate, not market data.